文献速递外周动脉疾病

在办公室导管室环境下经腘动脉入路治疗髂股动脉闭塞性疾病

Popliteal access for iliofemoral occlusive disease in the office-based catheter laboratory.
PubMed 文献 · J Vasc Surg · 2024-08-30

本研究在办公室导管室(OBL)环境下,对25例患者共27次经腘动脉入路治疗髂股动脉闭塞性病变的连续手术进行回顾性分析。技术成功率为92.5%(25/27),仅发生1例无症状的小腘动脉动静脉瘘,无其他并发症或主要不良心脏事件。作者认为经腘动脉入路安全有效,应被视为OBL环境下的有效替代选择。

要点

  • 在OBL环境下经腘动脉入路治疗髂股动脉闭塞性疾病的技术成功率为92.5%。
  • 仅发生1例无症状的小腘动脉动静脉瘘,无其他并发症或主要不良心脏事件。
  • 作者认为经腘动脉入路安全有效,应被视为OBL环境下的有效替代选择。

核心结论

  • 作者认为,对于复杂的髂股动脉疾病,经腘动脉入路安全有效,应被视为OBL环境下的有效替代选择。

研究设计与样本

  • 回顾性分析2018年10月至2023年10月在本中心OBL实施的1408例外周动脉疾病介入治疗中,连续27次经腘动脉入路治疗股动脉和髂动脉闭塞的手术。
  • 共25例患者(21例完全股动脉闭塞,6例严重狭窄),其中9例存在髂动脉病变。
  • 所有介入均在超声引导下使用微穿刺针完成,患者术后1小时出院。
  • 技术成功定义为靶病变完全开通,安全性评估覆盖围手术期和90天,通畅率通过临床、动脉双功超声及是否需要再干预评估,随访≤2年。

主要发现

  • 27次手术中25次成功开通闭塞(92.5%)。
  • 除1例无症状的小腘动脉动静脉瘘外,无并发症或主要不良心脏事件发生。
  • 25次成功手术中,3、6、12个月双功超声通畅率分别为19/20(95%)、11/15(69.3%)、11/13(61%)。
  • Rutherford分级从术前>4(24/27,89%)改善至术后<2:1个月为23/23(100%),3个月为19/20(95%),6个月为11/15(69.3%),12个月为11/13(61%)。
  • 免于再干预率:3个月为19/20(95%),6个月为13/15(86%),12个月为12/13(79%)。

临床怎么用

  • 作者认为经腘动脉入路安全有效,应被视为OBL环境下的有效替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Popliteal access as an alternative to conventional femoral access has not been reported in the office-based catheter laboratory setting (OBL) and may be perceived to have higher risks. The purpose of this study was to evaluate the safety and efficacy of popliteal access for the endovascular treatment of iliofemoral arterial occlusive disease in an OBL setting. METHODS: From October 2018 to October 2023, a total of 1408 interventions for peripheral artery disease were performed in our OBL. A cohort of 27 popliteal access consecutive procedures for femoral and iliac artery occlusions were studied. All interventions were done using a micropuncture needle under ultrasound guidance. All patients were discharged 1 hour after completion of the procedure. Indications for popliteal access were presence of aortoiliac stent grafts, aortobifemoral or aortoiliac bypasses, difficult contralateral or antegrade femoral access, and flush superficial femoral artery occlusions. Procedures were determined to be successful upon complete resolution of the target lesions and safety was measured perioperatively and at 90 days. Patency was determined clinically, by arterial duplex examination, and by need for reintervention for ≤2 years. RESULTS: We performed 27 popliteal access procedures in 25 patients (21 complete femoral artery occlusions, 6 severe stenosis). Iliac disease was present in nine. Indications for popliteal access were existing aortoiliac stent graft in 11, aortobifemiliac bypass in 4, noncrossable iliac occlusions in 3, failed antegrade femoral access in 4, flush superficial femoral artery occlusion in 3, and bilateral common femoral artery disease precluding access in 2. Trans-Atlantic Inter-Society Consensus classification preoperatively was B, 4; C, 4; and D, 19. Treatments included atherectomy/balloon angioplasty and stent in 12, balloon angioplasty and stenting in 4, atherectomy/balloon angioplasty in 5, and balloon angioplasty alone in 6. Successful opening of occlusions occurred in 25 of 27 patients (92.5%). No complications or major adverse cardiac events occurred, except one asymptomatic small popliteal arteriovenous fistula. Of the 25 successful procedures, the duplex patency at 3, 6, and 12 months was 19/20 (95%), 11/15 (69.3%), and 11/13 (61%). Rutherford Classification improved from a preoperative value of >4 in 24 of 27 (89%) to a postoperative value of <2 at 1 month in 23 of 23 (100%), at 3 months in 19 of 20 (95%), at 6 months in 11 of 15 (69.3%), and at 12 months in 11 of 13 (61%). Freedom from reintervention at 3 months occurred in 19 of 20 (95%), at 6 months in 13 of 15 (86%), and at 12 months in 12 of 13 (79%). CONCLUSIONS: Popliteal artery access for complex iliofemoral disease is safe and effective and should be considered as a valid alternative option in the OBL setting.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Shennib H, Teribery E, Evans A, et al. Popliteal access for iliofemoral occlusive disease in the office-based catheter laboratory. J Vasc Surg. 2024. PMID: 39216612. doi:10.1016/j.jvs.2024.08.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。